Loading...
•
Jun 30, 2022
Pulmonx Q2 2022 Earnings Report
Achieved record revenue driven by growth in the U.S. and improved gross margin.
Key Takeaways
Pulmonx reported a strong second quarter with worldwide revenue reaching $14.0 million, a 14% increase year-over-year. The company also achieved a gross margin of 75% and added 18 new U.S. treatment centers for Zephyr Valves.
Worldwide revenue reached a new high of $14.0 million, a 14% increase year-over-year and 19% on a constant currency basis.
Gross margin improved to 75% compared to 74% in the same period last year.
18 new U.S. treatment centers were added for Zephyr Valves, bringing the total to 248.
A study showed that Zephyr Valves improved cardiac function in severe COPD/emphysema patients.
Forward Guidance
Pulmonx expects full year 2022 revenue to be in the range of $55 million to $60 million and total operating expenses to be in the range of $100 million to $105 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...